Q4 EARNINGS: Quest beats forecasts; Zimmer faces more exchange rate pain
This article was originally published in Clinica
Executive Summary
Quest Diagnostics finished the year strongly, with its fourth quarter beating analyst expectations. Q4 sales of $1.88bn increased 7% year-on-year, marking the firm’s third consecutive quarter of growth, and were above analyst consensus of $1.85bn. Adjusted earnings of $1.08 per share were up from $1.03 per share in Q4 2013, and trumped analyst forecasts of $1.04.